{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_204647c28f059ea94978ec5f03ceea05b97febd2b190c78db987abd4f59ece8d","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_204647c28f059ea94978ec5f03ceea05b97febd2b190c78db987abd4f59ece8d","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"72bd0579a93fab0c2a02c921c628274399b3cc56f1e38a34ca793f1480c99b05","published":"Wed, 17 Jun 2026 00:00:00 -0400","receipt_hash":"72bd0579a93fab0c2a02c921c628274399b3cc56f1e38a34ca793f1480c99b05","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"72bd0579a93fab0c2a02c921c628274399b3cc56f1e38a34ca793f1480c99b05","observed_at":"2026-06-17T04:43:17.968423Z","parent_run_hash":"8f56c4deb22b28178ba7974d6ffc5ff17336d44c95dd94de80095705245fa113","published":"Wed, 17 Jun 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2606.17127v1 Announce Type: cross \nAbstract: Antimicrobial resistance causes to over a million deaths annually. Antimicrobial peptides (AMPs) are a promising solution, but generative AMP models are not yet ready to design peptides with non-natural amino acids and/or chemical modifications, which are essential for real-world peptide drugs. We present AMPGAN v3, a multi-objective conditional GAN that expands the generative vocabulary to D-amino acids and N/C-terminus modifications such as amidation. By separating adversarial and activity-aware supervision across two specialized discriminators, AMPGAN v3 substantially improves training stability and outperforms prior generative AMP models on external classifiers. We validated five candidates spanning three structural classes in vitro; two showed activity against Gram-positive strains, with the best candidate reaching MIC 8 {\\mu}g/mL against B. subtilis. To support downstream curation, we further present PepCraft, a multi-agent frame","title":"Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3","url":"https://arxiv.org/abs/2606.17127","vendor":"arxiv_cs_ai"},"summary":"arXiv:2606.17127v1 Announce Type: cross \nAbstract: Antimicrobial resistance causes to over a million deaths annually. Antimicrobial peptides (AMPs) are a promising solution, but generative AMP models are not yet ready to design peptides with non-natural amino acids and/or chemical modifications, which are essential for real-world peptide drugs. We present AMPGAN v3, a multi-objective conditional GAN that expands the generative vocabulary to D-amino acids and N/C-terminus modifications such as amidation. By separating adversarial and activity-aware supervision across two specialized discriminators, AMPGAN v3 substantially improves training stability and outperforms prior generative AMP models on external classifiers. We validated five candidates spanning three structural classes in vitro; two showed activity against Gram-positive strains, with the best candidate reaching MIC 8 {\\mu}g/mL against B. subtilis. To support downstream curation, we further present PepCraft, a multi-agent frame","title":"Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-06-17T04:43:17Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2606.17127"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:2066e18e706d635d707a8cf35879ae61a8cbf60985304e76e5e93912f35b0fc1f54c737053a537d4b78814cb0edfef3da55e2968ab98f7ce99810b9c259ac609","signer":"crovia.substrate","subject":{"observed_at":"2026-06-17T04:43:17Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2606.17127"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"4a62d1ff2a82485cc179e129c4962adb4a29df5cd0a8a0974c69e49c360f6cea","leaf_index":230932,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"fe4452292c97f4865610f3d1e9ed96689d6ac2f47c05d22d97be4bc940a503e9","side":"right"},{"sibling":"743c6fdc25622325edb7dd704402ad68939ee6454469d365a2c8200a71e46f36","side":"right"},{"sibling":"e11cdf369942a472333ce9da1b37db62cb0bec019c024a86f023fb56d4b6c053","side":"left"},{"sibling":"fe1c34d8743f0a6edd886782a55e9b5340a3ae68af354b5b98cee2b8b4a7c911","side":"right"},{"sibling":"89058150059fa791f48320ccd96dcf113012f88382777ba50eac9c86fc142d70","side":"left"},{"sibling":"53a58806ad794dc7abdba5c5adeb9a0ba8e12952d6a841d4180adb65f356cedf","side":"right"},{"sibling":"46a8ccd2dac1ed36480a55cc7afe558ddcd720bdcdac4bb787046b5795ed8399","side":"right"},{"sibling":"ce828166a6a4fc2ff2681c985a56053a1f8b683cc245e0b232fa5939310b3ad9","side":"right"},{"sibling":"ebbec9ce4bf43a3f5f71e2c07df4c91301abefa2da727a4d748099a74e980bc3","side":"right"},{"sibling":"1d74941c32baeab8cad08f8700cb49427d8256f231534f2a225b2bb3e84e4ff8","side":"left"},{"sibling":"d5b9f8b1a2c9f6a46e17982dfbe6ce1f3b5fa4e730220397f2253d114dcc8486","side":"left"},{"sibling":"d10d772a4984cae00e65ab24af21d1d260e475bbaae3f17871859eb705bd3999","side":"right"},{"sibling":"e79159853f2f35ddae8e3247d515e433c534277b287d65bbd77ae989aa4992fa","side":"right"},{"sibling":"3054319f1840cce0eaaf0bc4b1ae38e5bf8b6210927d924a750775cc7d77cca6","side":"right"},{"sibling":"0fd8b5059f279c4a4a6688de2472fdbc25543fee183df19b21dacca880354cff","side":"right"},{"sibling":"a04392fb9f2a3a620840e3b3fecd93d12e6d224e481c162389d8ae64e7194599","side":"left"},{"sibling":"c300cf0154c136afc09b1702a0be98f4ba5b6dc5cf57e8cc714ec1eaf4196eff","side":"left"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":232015,"merkle_root":"62bfb7809bb55667ad7eeebdb48267b9b2c1ee89bb808ea1e6d3a814a15aa402","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260617T133701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-06-17T13:39:59Z","sig_algorithm":"ed25519","signature":"930a3563c643cc7518d048b12a1f5392a96a5edce49533ba0a56f11b6cc69319bb1c800aacc46b52a6941c4d05dae255a45cac757d6093c971b96852c24f140e","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_204647c28f059ea94978ec5f03ceea05b97febd2b190c78db987abd4f59ece8d"}}